The Psychedelic News Feed https://psychedelicalpha.com Transistor (https://transistor.fm) https://feeds.transistor.fm/the-psychedelic-news-feed The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field. © 2026 Psychedelic Alpha 3bb209f1-d04d-5fdb-a469-b46953bd36a3 yes Josh Hardman en Mon, 02 Nov 2026 14:57:36 +0000 Mon, 02 Nov 2026 14:58:14 +0000 https://img.transistorcdn.com/7PI_uFd55BArz_piXGoXtUvxr9iODoJWYVfphaowB-4/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDc4/NWQ1YzQ4ODk0YjVm/NzE0OWNlOTkyOWI5/MTU3OC5wbmc.jpg The Psychedelic News Feed https://psychedelicalpha.com episodic Psychedelic Alpha The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. In it, Psychedelic Alpha Editor Josh Hardman provides a brief review of happenings across the field. The Psychedelic News Feed is the audio edition of Psychedelic Alpha's regular news roundup, bringing you a concise update from the worlds of psychedelic drug development, policy, and access. psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens Psychedelic Alpha No No Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine 4 4 Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine full bf6434d2-d31b-4ee7-9208-64b1227246ec https://share.transistor.fm/s/3b62bac6 In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Usona Institute files its psilocybin for major depressive disorder new drug application with FDA
  • FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine
  • We share our analysis of 610 public comments on FDA’s psychedelics docket
  • ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression
  • More takeaways from The Psychedelic Healthcare Forum
  • Other stories


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

]]> In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Usona Institute files its psilocybin for major depressive disorder new drug application with FDA
  • FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine
  • We share our analysis of 610 public comments on FDA’s psychedelics docket
  • ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression
  • More takeaways from The Psychedelic Healthcare Forum
  • Other stories


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

]]> Mon, 02 Nov 2026 14:57:36 +0000 Psychedelic Alpha Psychedelic Alpha 1399 In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Usona Institute files its psilocybin for major depressive disorder new drug application with FDA
  • FDA approves NRx Pharmaceuticals’ preservative-free generic ketamine
  • We share our analysis of 610 public comments on FDA’s psychedelics docket
  • ICER is set to review Compass Pathways’ psilocybin for treatment-resistant depression
  • More takeaways from The Psychedelic Healthcare Forum
  • Other stories


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/

]]> psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens No Josh Hardman Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing 3 3 Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing full f2f43e96-e278-421d-99df-714ace3d8e5a https://share.transistor.fm/s/3b38086c In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Early Notes from The Psychedelic Healthcare Forum
  • FDA Floats an Ibogaine Trial Design, Asks Field for Input
  • Compass Talks Pricing, Label and a Slow Launch
  • New Mexico Nears Medical Psilocybin Launch
  • Six More Potential Psychedelic Brand Names


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Early Notes from The Psychedelic Healthcare Forum
  • FDA Floats an Ibogaine Trial Design, Asks Field for Input
  • Compass Talks Pricing, Label and a Slow Launch
  • New Mexico Nears Medical Psilocybin Launch
  • Six More Potential Psychedelic Brand Names


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> Tue, 20 Oct 2026 12:09:25 +0100 Psychedelic Alpha Psychedelic Alpha 1031 In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:

  • Early Notes from The Psychedelic Healthcare Forum
  • FDA Floats an Ibogaine Trial Design, Asks Field for Input
  • Compass Talks Pricing, Label and a Slow Launch
  • New Mexico Nears Medical Psilocybin Launch
  • Six More Potential Psychedelic Brand Names


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens No Josh Hardman Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines 2 2 Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines full 1371833a-b0a7-4bfd-ab6d-2aff48e6fa29 https://share.transistor.fm/s/a3256dc5 In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:

  • Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)
  • California carves out $4.7M for psychedelic research
  • The DEA again moves to schedule 5 tryptamines
  • The PATH Caucus publishes its RFI white paper
  • Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 


]]> In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:

  • Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)
  • California carves out $4.7M for psychedelic research
  • The DEA again moves to schedule 5 tryptamines
  • The PATH Caucus publishes its RFI white paper
  • Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 


]]> Mon, 05 Oct 2026 12:34:53 +0100 Psychedelic Alpha Psychedelic Alpha 1302 In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through another busy two-week period in the field, including:

  • Oregon Health Authority’s decision to shelve its proposed doubling of fees levied on state-regulated psilocybin entities (ft. Taylor West, Exec. Director, Healing Advocacy)
  • California carves out $4.7M for psychedelic research
  • The DEA again moves to schedule 5 tryptamines
  • The PATH Caucus publishes its RFI white paper
  • Stanford and UCSF researchers call for “more aggressive” blinding in psychedelic trials (ft. Joshua Woolley, UCSF)


Read more:


The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 


]]> psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens No Josh Hardman Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers 1 1 Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers full e8f468e8-da45-4a47-ba78-7b3a86fe3dc7 https://share.transistor.fm/s/e4ec3f40 In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> Mon, 21 Sep 2026 11:29:28 +0100 Psychedelic Alpha Psychedelic Alpha 1094 In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including:

  • Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
  • A commentary published by top FDA staff outlining a model for psychedelic drug development
  • New Zealand’s approval of two psychiatrists to prescribe MDMA
  • And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.

Read more:

The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.


This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.


Send us your questions and comments at pod@psychedelicalpha.com 


Read more and join our newsletter at https://psychedelicalpha.com


Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.


Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ 

]]> psychedelics, psychedelic news, psychedelic medicine, psychedelic industry, clinical trials, drug development, biotechnology, neuroscience, mental health, FDA, regulation, biopharma, research, healthcare, psychedelic alpha, psychiatry, interventional psychiatry, neuroplastogens No Josh Hardman